Total Payments
$242,001
2019 Payments
$2,158
Companies
10
Transactions
134
Payment Breakdown by Category
Research$232,864 (96.2%)
Travel$6,757 (2.8%)
Food & Beverage$2,379 (1.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $232,864 | 69 | 96.2% |
| Travel and Lodging | $6,757 | 24 | 2.8% |
| Food and Beverage | $2,379 | 41 | 1.0% |
Payments by Type
Research
$232,864
69 transactions
General
$9,136
65 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Indivior Inc. | $143,079 | 9 | $0 (2018) |
| ACADIA Pharmaceuticals Inc | $86,806 | 45 | $0 (2018) |
| Allergan Inc. | $5,183 | 28 | $0 (2018) |
| Avanir Pharmaceuticals, Inc. | $2,040 | 15 | $0 (2019) |
| Shionogi Inc | $1,569 | 7 | $0 (2017) |
| F. Hoffmann-La Roche AG | $985.30 | 3 | $0 (2017) |
| Merck Sharp & Dohme Corporation | $953.94 | 10 | $0 (2017) |
| Biogen, Inc. | $859.47 | 12 | $0 (2018) |
| Alkermes, Inc. | $399.93 | 4 | $0 (2019) |
| Lundbeck LLC | $125.00 | 1 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2019 | $2,158 | 16 | Avanir Pharmaceuticals, Inc. ($2,040) |
| 2018 | $164,637 | 60 | Indivior Inc. ($142,291) |
| 2017 | $75,206 | 58 | ACADIA Pharmaceuticals Inc ($68,480) |
All Payment Transactions
134 individual payment records from CMS Open Payments — Page 1 of 6
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 08/03/2019 | Avanir Pharmaceuticals, Inc. | — | Travel and Lodging | In-kind items and services | $584.66 | General |
| 08/03/2019 | Avanir Pharmaceuticals, Inc. | — | Travel and Lodging | In-kind items and services | $63.24 | General |
| 08/02/2019 | Avanir Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $64.98 | General |
| 08/02/2019 | Avanir Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $29.98 | General |
| 08/02/2019 | Avanir Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $29.98 | General |
| 08/01/2019 | Avanir Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $49.98 | General |
| 08/01/2019 | Avanir Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $29.98 | General |
| 07/18/2019 | Avanir Pharmaceuticals, Inc. | — | Travel and Lodging | In-kind items and services | $455.61 | General |
| 05/30/2019 | Alkermes, Inc. | — | Food and Beverage | In-kind items and services | $117.98 | General |
| 05/10/2019 | Avanir Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $17.00 | General |
| 05/10/2019 | Avanir Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $17.00 | General |
| 05/10/2019 | Avanir Pharmaceuticals, Inc. | — | Travel and Lodging | In-kind items and services | $13.83 | General |
| 05/09/2019 | Avanir Pharmaceuticals, Inc. | — | Travel and Lodging | In-kind items and services | $186.16 | General |
| 05/09/2019 | Avanir Pharmaceuticals, Inc. | — | Travel and Lodging | In-kind items and services | $105.60 | General |
| 04/29/2019 | Avanir Pharmaceuticals, Inc. | — | Travel and Lodging | In-kind items and services | $341.08 | General |
| 04/29/2019 | Avanir Pharmaceuticals, Inc. | — | Travel and Lodging | In-kind items and services | $51.00 | General |
| 11/30/2018 | Biogen, Inc. | — | — | Cash or cash equivalent | $69.01 | Research |
| Study: A Phase 2, Randomized, Double-Blind, Multiple-Dose, Placebo-Controlled Study to Evaluate the Safety and Efficacy of BIIB104 in Subjects With Cognitive Impairment Associated With Schizophrenia (CIAS) | ||||||
| 11/30/2018 | Biogen, Inc. | — | — | Cash or cash equivalent | $44.88 | Research |
| Study: A Phase 2, Randomized, Double-Blind, Multiple-Dose, Placebo-Controlled Study to Evaluate the Safety and Efficacy of BIIB104 in Subjects With Cognitive Impairment Associated With Schizophrenia (CIAS) | ||||||
| 11/30/2018 | Biogen, Inc. | — | — | Cash or cash equivalent | $27.06 | Research |
| Study: A Phase 2, Randomized, Double-Blind, Multiple-Dose, Placebo-Controlled Study to Evaluate the Safety and Efficacy of BIIB104 in Subjects With Cognitive Impairment Associated With Schizophrenia (CIAS) | ||||||
| 11/30/2018 | Biogen, Inc. | — | — | Cash or cash equivalent | $13.53 | Research |
| Study: A Phase 2, Randomized, Double-Blind, Multiple-Dose, Placebo-Controlled Study to Evaluate the Safety and Efficacy of BIIB104 in Subjects With Cognitive Impairment Associated With Schizophrenia (CIAS) | ||||||
| 11/29/2018 | Biogen, Inc. | — | — | Cash or cash equivalent | $250.55 | Research |
| Study: A Phase 2, Randomized, Double-Blind, Multiple-Dose, Placebo-Controlled Study to Evaluate the Safety and Efficacy of BIIB104 in Subjects With Cognitive Impairment Associated With Schizophrenia (CIAS) | ||||||
| 11/29/2018 | Biogen, Inc. | — | — | Cash or cash equivalent | $66.36 | Research |
| Study: A Phase 2, Randomized, Double-Blind, Multiple-Dose, Placebo-Controlled Study to Evaluate the Safety and Efficacy of BIIB104 in Subjects With Cognitive Impairment Associated With Schizophrenia (CIAS) | ||||||
| 11/29/2018 | Biogen, Inc. | — | — | Cash or cash equivalent | $44.24 | Research |
| Study: A Phase 2, Randomized, Double-Blind, Multiple-Dose, Placebo-Controlled Study to Evaluate the Safety and Efficacy of BIIB104 in Subjects With Cognitive Impairment Associated With Schizophrenia (CIAS) | ||||||
| 11/29/2018 | Biogen, Inc. | — | — | Cash or cash equivalent | $26.02 | Research |
| Study: A Phase 2, Randomized, Double-Blind, Multiple-Dose, Placebo-Controlled Study to Evaluate the Safety and Efficacy of BIIB104 in Subjects With Cognitive Impairment Associated With Schizophrenia (CIAS) | ||||||
| 11/29/2018 | Biogen, Inc. | — | — | Cash or cash equivalent | $23.82 | Research |
| Study: A Phase 2, Randomized, Double-Blind, Multiple-Dose, Placebo-Controlled Study to Evaluate the Safety and Efficacy of BIIB104 in Subjects With Cognitive Impairment Associated With Schizophrenia (CIAS) | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| An Open-Label, Long-Term Safety and Tolerability Study of RBP-7000 in the Treatment of Subjects With Schizophrenia | Indivior Inc. | $123,460 | 7 |
| ACP-103-038 | ACADIA Pharmaceuticals Inc | $32,720 | 11 |
| ACP-103-042 | ACADIA Pharmaceuticals Inc | $21,485 | 9 |
| An Open-Label, Depot Buprenorphine RBP-6000 Treatment Extension Study in Subjects With Opioid Use Disorder | Indivior Inc. | $18,831 | 1 |
| ACP-103-035 | ACADIA Pharmaceuticals Inc | $17,406 | 18 |
| ACP-103-034 | ACADIA Pharmaceuticals Inc | $15,082 | 6 |
| A Randomized, Double-blind, Placebo-controlled, Multicenter, Efficacy and Safety Study of Rapastinel for Rapid Treatment of Symptoms of Depression and Suicidality in Adult Patients with Major Depressive Disorder | Allergan Inc. | $2,234 | 4 |
| A Phase 2, Randomized, Double-Blind, Multiple-Dose, Placebo-Controlled Study to Evaluate the Safety and Efficacy of BIIB104 in Subjects With Cognitive Impairment Associated With Schizophrenia (CIAS) | Biogen, Inc. | $859.47 | 12 |
| A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study To Assess the Efficacy, Safety, and Tolerability of Multiple Subcutaneous Injections of Depot Buprenorphine RBP-6000 100 mg and 300 mg Over 24 Weeks in Treatment-Seeking Subjects With Opioid Use Disorder | Indivior Inc. | $788.68 | 1 |
About Dr. Scott Bartley, M.D
Dr. Scott Bartley, M.D is a Psychiatry healthcare provider based in Dallas, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/10/2006. The National Provider Identifier (NPI) number assigned to this provider is 1255342143.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Scott Bartley, M.D has received a total of $242,001 in payments from pharmaceutical and medical device companies, with $2,158 received in 2019. These payments were reported across 134 transactions from 10 companies. The most common payment nature is "" ($232,864).
Ad
Practice Information
- Specialty Psychiatry
- Location Dallas, TX
- Active Since 08/10/2006
- Last Updated 04/27/2016
- Taxonomy Code 2084P0800X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1255342143
Products in Payments
- NUPLAZID (Drug) $86,806
- SUBLOCADE (Drug) $19,619
- VRAYLAR (Drug) $2,317
- Non-Covered Product (Drug) $985.30
- MK-8189 (Drug) $953.94
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Psychiatry Doctors in Dallas
Dr. Darin Okuda, M.d, M.D
Psychiatry — Payments: $739,134
Psychiatry $739,134
Augustus Rush, Md, MD
Psychiatry — Payments: $737,518
Psychiatry $737,518
Dr. Mary Knesevich, M.d, M.D
Psychiatry — Payments: $634,383
Psychiatry $634,383
Michael Downing, Md, MD
Psychiatry — Payments: $423,962
Psychiatry $423,962
Dr. Stephen Vobach, M.d, M.D
Psychiatry — Payments: $314,024
Psychiatry $314,024
Madhukar Trivedi, Md, MD
Psychiatry — Payments: $264,753
Psychiatry $264,753